Cell Therapy in Kidney Transplantation: Focus on Regulatory T Cells.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28465379.
- Also identified by DOI 10.1681/ASN.2016111206 and PMC identifier 5491296.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Renal transplantation is the renal replacement modality of choice for suitable candidates with advanced CKD or ESRD. Prevention of rejection, however, requires treatment with nonspecific pharmacologic immunosuppressants that carry both systemic and nephrologic toxicities. Use of a patient's own suppressive regulatory T cells (Tregs) is an attractive biologic approach to reduce this burden. Here, we review the immunologic underpinnings of Treg therapy and technical challenges to developing successful cell therapy. These issues include the selection of appropriate Treg subsets, <i>ex vivo</i> Treg expansion approaches, how many Tregs to administer and when, and how to care for patients after Treg administration.
Medical subject headings
- Graft Rejection
- Immunosuppression Therapy
- Kidney Transplantation
- T-Lymphocytes, Regulatory